Gilead seals $2bn deal for Arcus’ pipeline 28-May-2020 By Ben Hargreaves Gilead signs 10-year deal with Arcus to gain access to its clinical and preclinical pipeline of immuno-oncology candidates.
Sanofi set to sell Regeneron shares worth $13bn 26-May-2020 By Ben Hargreaves Sanofi will sell close to 23 million shares of Regeneron stock, with plans to use the funds to support acqusitions.
Merck leaps into COVID-19 battle with three developments 26-May-2020 By Ben Hargreaves The company announces three deals on the same day, including an acquisition and two partnership deals against COVID-19.
Novartis’ gene therapy approved in Europe, talks ongoing on price 21-May-2020 By Ben Hargreaves The most expensive therapy in the world receives conditional approval in Europe.
UK injects funds into COVID-19 vaccine, puts citizens front of queue 19-May-2020 By Ben Hargreaves UK government will invest into an existing vaccine developed by the Oxford University and will speed up completion of a vaccine manufacturing center.
Sanofi retracts US-first stance on COVID-19 vaccine 18-May-2020 By Ben Hargreaves The French company bows to pressure from the French government to state that there will be no preferential supply to US of potential vaccine.
US outlines plan for readying coronavirus vaccine by start of 2021 18-May-2020 By Ben Hargreaves The US government provided details on ‘Operation Warp Speed’ and who will take leadership of the project.
FDA refuses to file BMS treatment over manufacturing concerns 14-May-2020 By Ben Hargreaves US FDA knocks back BMS and bluebird’s application for ide-cel, demanding further details on CMC portion of BLA.
Dyno launches with gene therapy partnership alongside Novartis 11-May-2020 By Ben Hargreaves The biotech emerges from stealth mode with two partnerships potentially worth in excess of $2bn.
Menarini set to acquire Stemline for $677m 07-May-2020 By Ben Hargreaves Menarini adds Stemline’s lead product, Elzonris, and its presence in the US with buyout deal.
Alexion in $1.4bn buyout for reversal agent 07-May-2020 By Ben Hargreaves Alexion agrees deal for Portola to gain access to its lead product, Andexxa, a treatment that counteracts anticoagulants.
How to prevent another COVID-19? ‘Invest in infrastructure’ 06-May-2020 By Ben Hargreaves CEO of Berkeley Lights talks about the company’s work to identify antibodies against COVID-19 and what the long-term picture looks like.
Sanofi insulin biosimilar close to European entrance 05-May-2020 By Ben Hargreaves Sanofi’s insulin aspart biosimilar receives positive opinion from the EMA’s CHMP.
Immunomedics closes $459m stock offering to launch drug, scale manufacture 04-May-2020 By Ben Hargreaves April saw the company add new CEO, receive approval for lead ADC drug, and launch a public offering of stock.
Sanofi receives FDA approval for quadrivalent meningococcal vaccine 28-Apr-2020 By Ben Hargreaves The company receives approval for MenQuadfi to prevent meningococcal disease.
